{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T07:31:35Z","timestamp":1795073495665,"version":"4.10.2"},"reference-count":52,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Silencing the expression of the double homeobox 4 (DUX4) gene offers great potential for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Several research groups have recently reported promising results using systemic antisense therapy in a transgenic small animal model of FSHD, the ACTA1-MCM\/FLExDUX4 mouse model. However, the treatment was applied in non-DUX4-induced mice or shortly after DUX4 activation, which resulted in conditions that do not correctly represent the situation in a clinic. Here, we generated progressive FSHD-like pathology in ACTA1-MCM\/FLExDUX4 mice and then treated the animals with vivoPMO-PACS4, an antisense compound that efficiently downregulates DUX4. To best mimic the translation of this treatment in clinical settings, the systemic antisense oligonucleotide administration was delayed to 3 weeks after the DUX4 activation so that the pathology was established at the time of the treatment. The chronic administration of vivoPMO-PACS4 for 8 weeks downregulated the DUX4 expression by 60%. Consequently, the treated mice showed an increase by 18% in body-wide muscle mass and 32% in muscle strength, and a reduction in both myofiber central nucleation and muscle fibrosis by up to 29% and 37%, respectively. Our results in a more suitable model of FSHD pathology confirm the efficacy of vivoPMO-PACS4 administration, and highlight the significant benefit provided by the long-term treatment of the disease.<\/jats:p>","DOI":"10.3390\/biomedicines10071623","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T07:51:56Z","timestamp":1657180316000},"page":"1623","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-9607","authenticated-orcid":false,"given":"Ngoc","family":"Lu-Nguyen","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, School of Life Sciences and the Environment, Royal Holloway University of London, Egham TW20 0EX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dickson","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, School of Life Sciences and the Environment, Royal Holloway University of London, Egham TW20 0EX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Malerba","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, School of Life Sciences and the Environment, Royal Holloway University of London, Egham TW20 0EX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9417-4073","authenticated-orcid":false,"given":"Linda","family":"Popplewell","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, School of Life Sciences and the Environment, Royal Holloway University of London, Egham TW20 0EX, UK"},{"name":"National Horizons Centre, Teesside University, Darlington DL1 1HG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1399-0004.2009.01158.x","article-title":"Facioscapulohumeral muscular dystrophy: Epidemiological and molecular study in a north-east Italian population sample","volume":"75","author":"Mostacciuolo","year":"2009","journal-title":"Clin. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-based incidence and prevalence of facioscapulohumeral dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ncl.2014.04.003","article-title":"Facioscapulohumeral Muscular Dystrophy","volume":"32","author":"Statland","year":"2014","journal-title":"Neurol. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nmd.2003.07.001","article-title":"Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD)","volume":"14","author":"Tonini","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1180","DOI":"10.1212\/WNL.0000000000008123","article-title":"Patient-Reported Symptoms in Facioscapulohumeral Muscular Dystrophy (PRISM-FSHD)","volume":"93","author":"Hamel","year":"2019","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00415-017-8525-9","article-title":"Respiratory involvement in ambulant and non-ambulant patients with facioscapulohumeral muscular dystrophy","volume":"264","author":"Moreira","year":"2017","journal-title":"J. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.nmd.2017.03.008","article-title":"Respiratory function in facioscapulohumeral muscular dystrophy 1","volume":"27","author":"Wohlgemuth","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/mus.27493","article-title":"Systemic manifestations and symptom burden of facioscapulohumeral muscular dystrophy in a referral cohort","volume":"65","author":"Kelly","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jns.2009.05.014","article-title":"Sleep disordered breathing in facioscapulohumeral muscular dystrophy","volume":"285","author":"Frusciante","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/mus.24218","article-title":"Restrictive lung involvement in facioscapulohumeral muscular dystrophy","volume":"50","author":"Scully","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/mus.26717","article-title":"Respiratory muscle weakness in facioscapulohumeral muscular dystrophy","volume":"60","author":"Henke","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"18157","DOI":"10.1073\/pnas.0708659104","article-title":"DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1","volume":"104","author":"Dixit","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","first-page":"540","article-title":"DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo","volume":"69","author":"Ba","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Vanderplanck, C., Ansseau, E., Charron, S., Stricwant, N., Tassin, A., Laoudj-Chenivesse, D., Wilton, S., Copp\u00e9e, F., and Belayew, A. (2011). The FSHD Atrophic Myotube Phenotype Is Caused by DUX4 Expression. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0026820"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2016.111","article-title":"Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics","volume":"24","author":"Chen","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1073\/pnas.1909649117","article-title":"Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy","volume":"117","author":"Lim","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1093\/hmg\/ddt314","article-title":"Wnt\/\u03b2-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells","volume":"22","author":"Block","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13395-017-0134-x","article-title":"BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells","volume":"7","author":"Campbell","year":"2017","journal-title":"Skelet. Muscle"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11837","DOI":"10.1074\/jbc.RA118.002633","article-title":"Protein kinase A activation inhibits DUX4 gene expression in myotubes from patients with facioscapulohumeral muscular dystrophy","volume":"293","author":"Cruz","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/mt.2012.68","article-title":"RNA Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy","volume":"20","author":"Wallace","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.omtn.2021.09.010","article-title":"Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy","volume":"26","author":"Bouwman","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.119.259663","article-title":"Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy","volume":"370","author":"Oliva","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-27430-1","article-title":"Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy","volume":"12","author":"Saad","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2017.12.005","article-title":"Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD","volume":"8","author":"Wallace","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.omtm.2020.12.001","article-title":"Targeted epigenetic repression by CRISPR\/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD","volume":"20","author":"Himeda","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1093\/nar\/gkaa146","article-title":"G-quadruplex ligands mediate downregulation of DUX4 expression","volume":"48","author":"Ciszewski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.119.264689","article-title":"p38\u03b1 Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular Dystrophy","volume":"374","author":"Rojas","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.omtn.2020.10.028","article-title":"A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy","volume":"22","author":"Mariot","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"eaaw7099","DOI":"10.1126\/sciadv.aaw7099","article-title":"Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy","volume":"5","author":"DeSimone","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"eaaw7781","DOI":"10.1126\/sciadv.aaw7781","article-title":"A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death","volume":"5","author":"Bosnakovski","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.omtn.2020.12.004","article-title":"Designed U7 snRNAs inhibit DUX4 expression and improve FSHD-associated outcomes in DUX4 overexpressing cells and FSHD patient myotubes","volume":"23","author":"Rashnonejad","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ymthe.2020.10.010","article-title":"DUX4 Transcript Knockdown with Antisense 2\u2032-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy","volume":"29","author":"Lim","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/hmg\/ddab136","article-title":"Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model","volume":"30","author":"Malerba","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lu-Nguyen, N., Malerba, A., Pineda, M.M.A., Dickson, G., and Popplewell, L.J. (Hum. Gene Ther., 2022). Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM\/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy, Hum. Gene Ther., (online ahead of print).","DOI":"10.1089\/hum.2021.251"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13395-022-00287-8","article-title":"Meeting report: The 2021 FSHD International Research Congress","volume":"12","author":"Jagannathan","year":"2022","journal-title":"Skelet. Muscle"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13395-020-00227-4","article-title":"Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity","volume":"10","author":"Jones","year":"2020","journal-title":"Skelet. Muscle"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Jones, T., and Jones, P.L. (2018). A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0192657"},{"key":"ref_38","first-page":"3091","article-title":"Functional muscle recovery following dystrophin and myostatin exon splice modulation in aged mdx mice","volume":"28","author":"Ferry","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/cpmo.19","article-title":"Histopathological Evaluation of Skeletal Muscle with Specific Reference to Mouse Models of Muscular Dystrophy","volume":"6","author":"Terry","year":"2016","journal-title":"Curr. Protoc. Mouse Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"ref_41","first-page":"1","article-title":"MuscleJ: A high-content analysis method to study skeletal muscle with a new Fiji tool","volume":"8","author":"Hardy","year":"2018","journal-title":"Skelet. Muscle"},{"key":"ref_42","first-page":"21","article-title":"Power Comparisons of Shapiro-Wilk, Kolmogorov-Smirnov, Lilliefors and Anderson-Darling Tests","volume":"2","author":"Razali","year":"2011","journal-title":"J. Stat. Model. Anal."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/hmg\/ddaa164","article-title":"Skeletal muscle regeneration in facioscapulohumeral muscular dystrophy is correlated with pathological severity","volume":"29","author":"Banerji","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3233\/JND-200543","article-title":"Correlation Between Quantitative MRI and Muscle Histopathology in Muscle Biopsies from Healthy Controls and Patients with IBM, FSHD and OPMD","volume":"7","author":"Lassche","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1038\/s41598-017-04896-y","article-title":"The effect of calorie restriction on mouse skeletal muscle is sex, strain and time-dependent","volume":"7","author":"Boldrin","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/hmg\/ddw018","article-title":"Collagen VI deficiency reduces muscle pathology, but does not improve muscle function, in the \u03b3-sarcoglycan-null mouse","volume":"25","author":"Hamlyn","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"dmm049016","DOI":"10.1242\/dmm.049016","article-title":"Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models","volume":"14","author":"Nunes","year":"2021","journal-title":"Dis. Model. Mech."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41467-017-00730-1","article-title":"Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model","volume":"8","author":"Bosnakovski","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e123538","DOI":"10.1172\/jci.insight.123538","article-title":"AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD","volume":"3","author":"Giesige","year":"2018","journal-title":"JCI Insight"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.nmd.2013.01.005","article-title":"Infantile facioscapulohumeral muscular dystrophy revisited: Expansion of clinical phenotypes in patients with a very short EcoRI fragment","volume":"23","author":"Chen","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1582-4934.2012.01647.x","article-title":"DUX4 expression in FSHD muscle cells: How could such a rare protein cause a myopathy?","volume":"17","author":"Tassin","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1623\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:43:44Z","timestamp":1760139824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071623"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071623","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]}}}